Work at Axcynsis Therapeutics Pte. Ltd. has led to the creation of antibody-drug conjugates (ADCs) comprising antibodies covalently linked to ecteinascidin and lurbinectedin derivatives through a linker; they are reported to be useful for the treatment of cancer.
Innate Pharma SA has obtained IND clearance from the FDA for IPH-4502, its novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) conjugated to exatecan targeting Nectin-4 in solid tumors. In nonclinical models, IPH-45 was well tolerated and showed antitumor efficacy in vitro and in vivo.
OS Therapies Inc. has announced the development and in vitro concept data for two novel tunable antibody-drug conjugate (tADC) therapeutic candidates leveraging the company’s proprietary Silinker technology.
OS Therapies Inc. has announced promising data in animal models of ovarian cancer for its first therapeutic candidate developed based upon its proprietary tunable antibody-drug conjugate (tADC) platform.
Bivictrix Therapeutics plc has announced promising initial in vivo data for BVX-002, its lead solid tumor bispecific antibody-drug conjugate (ADC) program. The preclinical study is investigating BVX-002 dosed once weekly, with a total of four doses given, in a murine xenograft model of ovarian cancer, using the human cell line OVCAR-3.
Chengdu Duote Antibody Pharmaceutical Co. Ltd. has described antibody-drug conjugates comprising antibody or antigen-binding fragments covalently linked to eribulin derivatives through a linker reported to be useful for the treatment of cancer.
Adcendo ApS and Multitude Therapeutics Inc. have signed a licensing agreement for the development of a highly differentiated antibody-drug conjugate (ADC) targeting tissue factor, designated ADCE-T02.
Yarrow Therapeutics Inc. has divulged antibody-drug conjugates comprising antibody or antigen binding fragments covalently linked to ecteinascidin derivatives through linkers reported to be useful for the treatment of cancer.
Otsuka Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising humanized monoclonal antibody targeting syndecan-1 (SDC1; SYND1; CD138) covalently linked to anticancer and/or cytotoxic agents through linkers reported to be useful for the treatment of cancer.
RSS
